11. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Issue 10020 (20th February 2016) Authors: Dreyling, Martin; Jurczak, Wojciech; Jerkeman, Mats; Silva, Rodrigo Santucci; Rusconi, Chiara; Trneny, Marek; Offner, Fritz; Caballero, Dolores; Joao, Cristina; Witzens-Harig, Mathias; Hess, Georg; Bence-Bruckler, Isabelle; Cho, Seok-Goo; Bothos, John; Goldberg, Jenna D; Enny, Christopher; Traina... Journal: Lancet Issue: Volume 387:Issue 10020(2016) Page Start: 770 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. (17th November 2021) Authors: Balasubramanian, Sriram; Hodkinson, Brendan; Schuster, Stephen J.; Fowler, Nathan H.; Trotman, Judith; Hess, Georg; Cheson, Bruce D.; Schaffer, Michael; Sun, Steven; Deshpande, Sanjay; Vermeulen, Jessica; Salles, Gilles; Gopal, Ajay K. Journal: Cancer medicine Issue: Volume 11:Number 1(2022) Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. Issue 5 (13th May 2022) Authors: Dreyling, Martin; Goy, Andre; Hess, Georg; Kahl, Brad S.; Hernández-Rivas, José-Ángel; Schuier, Natasha; Qi, Keqin; Deshpande, Sanjay; Zhu, Angeline; Parisi, Lori; Wang, Michael L. Journal: HemaSphere Issue: Volume 6:Issue 5(2022) Page Start: e712 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. MTOR inhibition in diffuse large B-cell lymphoma: new hope?. Issue 7 (July 2016) Authors: Hess, Georg Journal: Lancet Issue: Volume 3:Issue 7(2016) Page Start: e302 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients. (30th March 2015) Authors: Österborg, Anders; Wierda, William G.; Mayer, Jiří; Hess, Georg; Hillmen, Peter; Schetelig, Johannes; Schuh, Anna; Smolej, Lukáš; Beck, Christian; Dreyfus, Brigitte; Hellman, Andrzej; Kozlowski, Piotr; Pfreundschuh, Michael; Rizzi, Rita; Spacek, Martin; Phillips, Jennifer L.; Gupta, Ira V.; Willi... Journal: British journal of haematology Issue: Volume 170:Number 1(2015:Jul.) Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry. Issue 5 (8th May 2022) Authors: Tilch, Marie-Kristin; Visco, Carlo; Kinda, Sandra; Hermine, Olivier; Kohn, Milena; Besson, Caroline; Lamure, Sylvain; Duléry, Rémy; Ragaini, Simone; Eyre, Toby A.; Van Meerten, Tom; Ohler, Anke; Eckerle, Steffen; Dreyling, Martin; Hess, Georg; Giné, Eva; Gomes da Silva, Maria Journal: HemaSphere Issue: Volume 6:Issue 5(2022) Page Start: e0711 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies. (18th August 2017) Authors: Rule, Simon; Dreyling, Martin; Goy, Andre; Hess, Georg; Auer, Rebecca; Kahl, Brad; Cavazos, Nora; Liu, Black; Yang, Shiyi; Clow, Fong; Goldberg, Jenna D.; Beaupre, Darrin; Vermeulen, Jessica; Wildgust, Mark; Wang, Michael Journal: British journal of haematology Issue: Volume 179:Number 3(2017) Page Start: 430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Issue 12 (2nd December 2015) Authors: Niesvizky, Ruben; Badros, Ashraf Z.; Costa, Luciano J.; Ely, Scott A.; Singhal, Seema B.; Stadtmauer, Edward A.; Haideri, Nisreen A.; Yacoub, Abdulraheem; Hess, Georg; Lentzsch, Suzanne; Spicka, Ivan; Chanan-Khan, Asher A.; Raab, Marc S.; Tarantolo, Stefano; Vij, Ravi; Zonder, Jeffrey A.; Huang, ... Journal: Leukemia & lymphoma Issue: Volume 56:Issue 12(2015:Dec.) Page Start: 3320 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. (29th September 2017) Authors: Einsele, Hermann; Engelhardt, Monika; Tapprich, Christoph; Müller, Jürgen; Liebisch, Peter; Langer, Christian; Kropff, Martin; Mügge, Lars O.; Jung, Wolfram; Wolf, Hans‐Heinrich; Metzner, Bernd; Hart, Christina; Gramatzki, Martin; Hertenstein, Bernd; Pfreundschuh, Michael; Rösler, Wolf; Fischer, ... Journal: British journal of haematology Issue: Volume 179:Number 4(2017) Page Start: 586 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study. (28th December 2014) Authors: Kirschey, Sebastian; Flohr, Thomas; Wolf, Hans H.; Frickhofen, Norbert; Gramatzki, Martin; Link, Hartmut; Basara, Nadezda; Peter, Norma; Meyer, Ralf G.; Schmitz, Norbert; Weidmann, Eckhart; Banat, Andre; Schulz, Andrea; Kolbe, Karin; Derigs, Guenter; Theobald, Matthias; Hess, Georg Journal: British journal of haematology Issue: Volume 168:Number 6(2015:Mar.) Page Start: 824 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗